Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

436.38 -9.41 (-2.11%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 03, 2022

Via Benzinga

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.

Via Benzinga

Why Is Alnylam (ALNY) Stock Up 50% Today? ↗

August 03, 2022

ALNY stock is quickly moving higher as Wall Street weighs Alnylam's encouraging results for a hard-to-treat condition.

Via InvestorPlace

Expert Ratings for Alnylam Pharmaceuticals ↗

July 15, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Via Benzinga

What Is Going on With Helius Medical (HSDT) Stock Today? ↗

August 03, 2022

Helius Medical (HSDT) stock is rocketing higher on Wednesday despite a lack of news from the medical device holding company.

Via InvestorPlace

Alnylam Shares Shoot Higher Following Positive Clinical Results From Late-Stage ATTR Amyloidosis Therapeutics ↗

August 03, 2022

Alnylam (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why ↗

August 03, 2022

Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study.

Via Investor's Business Daily

Why Alnylam Pharma Shares Are Trading Higher During Premarket Session ↗

August 03, 2022

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) shares are rallying after upbeat data from APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 03, 2022

Via Benzinga

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

August 03, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators

August 02, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alnylam Pharmaceuticals: Q2 Earnings Insights ↗

July 28, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q2 earnings results on Thursday, July 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

July 28, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity

July 27, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform ↗

July 25, 2022

Via Benzinga

Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results

July 18, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine ↗

July 15, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022 ↗

July 13, 2022

Upgrades

Via Benzinga

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 06, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 05, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

5 Best And Worst Performing Large-Cap Stocks In June 2022 ↗

July 05, 2022

Over the past decade or so, these large-cap stocks have outperformed their smaller peers. Let’s take a look at the five best and worst performing large-cap stocks in June 2022.

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

June 27, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022 ↗

June 27, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate ↗

June 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate ↗

June 13, 2022

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary...

Via Benzinga

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

June 13, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today